Väljaminev kiriAvalik
Vastused küsimustele
Ravimiamet · 16. juuli 2024
- Viit
- JUH-8/2579-2
- Registreeritud
- 16. juuli 2024
- Dokumendi liik
- Väljaminev kiri
- Adressaat
- Thomson Reuters Corporation
- Saabumis/saatmisviis
- Outlook
- Funktsioon
- JUH Juhtimine
- Sari
- JUH-8 Kirjavahetus pressiga
- Toimik
- JUH-8/2024
- Vastutaja
- Carmen Katariina Sikk (RA)
Sisu (failidest)
Saatja: "Carmen Katariina Sikk" <[email protected]>
Saaja: "Kärolin Jenas" <[email protected]>
Teema: Ed: Journalist query - semaglutide
Kuupäev: 2024-07-03 06:29
Saatja: Carmen Katariina Sikk
Saatmisaeg: kolmapäev, 3. juuli 2024 09:28
Adressaat: 'Silver, Andrew (Reuters)' <[email protected]>
Teema: Vs: Journalist query - semaglutide
Hello, Andrew!
Aet Viispert (head of the department of marketing authorisations)
answered:
Determination of whether the patent is applicable is the responsibility of
the applicant/marketing authorisation holder. During the term of
protection of the patent or SPC of the reference medicinal product, there
can be no commercial use of the resulting final medicinal products
obtained for the purposes of the regulatory approval process.
The competent authorities responsible for the authorisation of medicines
cannot assess the marketing authorisation applications and make decisions
based on the patent or SPC status of the reference medicinal product.
Carmen Katariina Sikk
Agency of Medicines
Head of Communications
Tel 737 4140
[email protected]
<mailto:[email protected]>
Saatja: Silver, Andrew (Reuters) <[email protected]
<mailto:[email protected]> >
Saatmisaeg: esmaspäev, 1. juuli 2024 18:19
Adressaat: Carmen Katariina Sikk <[email protected]
<mailto:[email protected]> >
Teema: Journalist query - semaglutide
Hi I’m a journalist with Reuters in Shanghai, I write about health and
pharma.
I’ve heard there may be some countries where there is no patent on
semaglutide. Do you know if any companies in those countries are producing
oral pill or injectible versions of semaglutide drugs (i.e. rybelsus
generic/biosimilar) for consumers that are sold to people based in
countries with patent protection (i.e. directly or via third-party
distributors) like Estonia, and are there any examples you can share? Or
how common such a phenomenon is, what countries are involved?
Appreciate your time,
-Andrew